IL325831A - פורמולציות של מעכבי rock2 עבור הפרעות במערכת העצבים המרכזית - Google Patents

פורמולציות של מעכבי rock2 עבור הפרעות במערכת העצבים המרכזית

Info

Publication number
IL325831A
IL325831A IL325831A IL32583126A IL325831A IL 325831 A IL325831 A IL 325831A IL 325831 A IL325831 A IL 325831A IL 32583126 A IL32583126 A IL 32583126A IL 325831 A IL325831 A IL 325831A
Authority
IL
Israel
Prior art keywords
formulations
cns disorders
rock2 inhibitors
rock2
inhibitors
Prior art date
Application number
IL325831A
Other languages
English (en)
Original Assignee
Graviton Bioscience Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Graviton Bioscience Bv filed Critical Graviton Bioscience Bv
Publication of IL325831A publication Critical patent/IL325831A/he

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL325831A 2023-07-17 2024-07-17 פורמולציות של מעכבי rock2 עבור הפרעות במערכת העצבים המרכזית IL325831A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363514042P 2023-07-17 2023-07-17
PCT/IB2024/056936 WO2025017500A1 (en) 2023-07-17 2024-07-17 Formulations of rock2 inhibitors for cns disorders

Publications (1)

Publication Number Publication Date
IL325831A true IL325831A (he) 2026-03-01

Family

ID=92302638

Family Applications (1)

Application Number Title Priority Date Filing Date
IL325831A IL325831A (he) 2023-07-17 2024-07-17 פורמולציות של מעכבי rock2 עבור הפרעות במערכת העצבים המרכזית

Country Status (3)

Country Link
AU (1) AU2024294840A1 (he)
IL (1) IL325831A (he)
WO (1) WO2025017500A1 (he)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026053168A1 (en) * 2024-09-06 2026-03-12 Graviton Bioscience Bv Amorphous forms of a rock2 inhibitor and formulations thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4201178C2 (de) 1992-01-17 1995-12-07 Alfatec Pharma Gmbh Verfahren zur Herstellung von Weichgelatinekapseln nach einem Tropfverfahren
NL1009107C2 (nl) 1997-11-12 1999-06-15 Banner Pharmacaps Inc Gelatine-uitspreidende doos met meervoudige, aanpasbare poortklep en meerlagig zacht gel.
JP2002529398A (ja) 1998-11-11 2002-09-10 バイオプログレス・テクノロジー・インターナショナル・インコーポレイテッド 薬剤配達系のためのカプセル
US6340473B1 (en) 1999-07-07 2002-01-22 R.P. Scherer Technologies, Inc. Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same
US10857157B2 (en) * 2015-01-26 2020-12-08 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
WO2019000682A1 (zh) 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
CN110582489B (zh) 2017-06-30 2023-10-27 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
US10323023B2 (en) 2017-06-30 2019-06-18 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
EA202090306A1 (ru) * 2017-07-21 2020-06-25 Кадмон Корпорейшн, Ллк ИНГИБИТОРЫ Rho-АССОЦИИРОВАННОЙ, СОДЕРЖАЩЕЙ СУПЕРСПИРАЛЬ ПРОТЕИНКИНАЗЫ
CN112969694B (zh) 2018-11-09 2023-06-13 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其用途
BR112021017354A2 (pt) 2019-03-01 2021-11-16 Beijing Tide Pharmaceutical Co Ltd Método para o tratamento de doença hepática adiposa e/ou esteatoepatite
CA3144113A1 (en) 2019-06-25 2020-12-30 Beijing Tide Pharmaceutical Co., Ltd. Method for treating idiopathic pulmonary fibrosis
KR20230058466A (ko) 2020-08-31 2023-05-03 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 신규한 rho-연관 단백질 인산화효소 억제제의 제조 방법 및 제조 방법 중의 중간체
JP2023539276A (ja) * 2020-08-31 2023-09-13 ベイジン タイド ファーマシューティカル カンパニー リミテッド Rho関連タンパク質キナーゼ阻害剤の塩、その固体形態、その調製方法およびその使用
KR20240095429A (ko) * 2021-11-16 2024-06-25 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Rock2 억제제의 나노결정 제제 및 이의 제조방법

Also Published As

Publication number Publication date
AU2024294840A1 (en) 2026-02-26
WO2025017500A1 (en) 2025-01-23

Similar Documents

Publication Publication Date Title
IL295364B1 (he) נגזרות פסילוצין כחומר פסיכודלי סרוטונרגי לטיפול בהפרעות של מערכת העצבים המרכזית
IL316616A (he) מעכבי rock2
IL315722A (he) תרכובות אינדאזול מותמרות עם פיפראזין כמעכבי parg
EP4100403A4 (en) 3-PYRROLIDINE-INDOLE DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISEASES
IL325831A (he) פורמולציות של מעכבי rock2 עבור הפרעות במערכת העצבים המרכזית
ZA202212146B (en) Inhibitors of nek7 kinase
EP4452967A4 (en) Inhibitors of sars-cov-2
IL325528A (he) שימוש בגליצרידים בפורמולציות lnp
IL325596A (he) תכשירי רוקחות למעכבים של nek7 קינאז
CA3298108A1 (en) Formulations of rock2 inhibitors for cns disorders
IL325832A (he) פורמולציות ושימושים של מעכבי rock2 ל- als
IL309182A (he) מעכבי פרוטיאז לטיפול בזיהומי נגיף הקורונה
EP4153616A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES
EP4100065A4 (en) USE OF MIRNA-485 INHIBITORS TO TREAT TAUOPATHY
IL319571A (he) R-טריהקסיפנידיל לטיפול בהפרעות תנועה
GB202201708D0 (en) Compositions for oral delivery of biotherapeutics
CA3273444A1 (en) Inhibitors of rock2
HK40122640A (en) Inhibitors of rock2
HK40076349A (en) Allogeneic composition for treatment of cns disorders
IL320731A (he) הרכבים ושיטות למחלות מערכת העצבים המרכזית
HK40082232A (en) Compounds and compositions for treating cns disorders
HK40082254A (en) Compounds and compositions for treating cns disorders
IL317760A (he) תולדות בנזוקרבאזול כמעכבי drp1
CA3297265A1 (en) Pharmaceutical compositions for inhibitors of nek7 kinase
GB202203181D0 (en) Inhibitors of elF4A